Dolutegravir (Tivicay) is an integrase inhibitor approved to treat HIV infection. It is generally dosed as a single 50mg daily tablet for adults and adolescents over 12 years old and weighing at least 40kg. Lower doses are needed when taken with certain other drugs. It is metabolized in the liver and has a half-life of 14 hours. Common side effects include abnormal liver function, fat redistribution, hyperglycemia, insomnia, and headache. Dolutegravir should not be taken with certain antacids, supplements, or seizure and tuberculosis medications due to potential drug interactions.